The Efficacy and Safety of Thymosin-α1 in Patients With HBV-related ACLF
Status:
Completed
Trial end date:
2019-07-30
Target enrollment:
Participant gender:
Summary
A randomized controlled trial to evaluate efficacy and safety of Thymosin-α1 administration
in patients with HBV-related Acute-on-chronic liver failure.